All In Biotech

Drug Trial Radar · NCT06719128

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Dec 6, 2024

Primary completion

Aug 25, 2025

Study completion Aug 25, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Dec 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.

Conditions

  • Hepatic Insufficiency
  • Healthy

Interventions

  • OlomorasibDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum observed concentration (Cmax) of OlomorasibTime frame: Predose on Day 1 up to 96 hours postdose
  2. PK: Area under the concentration versus time curve from time zero to infinity (AUC0-inf) of OlomorasibTime frame: Predose on Day 1 up to 96 hours postdose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Orange County Research Center

    Lake Forest, California

  • Clinical Pharmacology of Miami

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

  • American Research Corporation at Texas Liver Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.